These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 21037119)

  • 1. Neuropsychiatric complications of efavirenz therapy: suggestions for a new research paradigm.
    Sütterlin S; Vögele C; Gauggel S
    J Neuropsychiatry Clin Neurosci; 2010; 22(4):361-9. PubMed ID: 21037119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.
    Muñoz-Moreno JA; Fumaz CR; Ferrer MJ; González-García M; Moltó J; Negredo E; Clotet B
    AIDS Rev; 2009; 11(2):103-9. PubMed ID: 19529750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz.
    Drury A; Gleadow-Ware S; Gilfillan S; Ahrens J
    Malawi Med J; 2018 Mar; 30(1):40-45. PubMed ID: 29868159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
    Mills AM; Antinori A; Clotet B; Fourie J; Herrera G; Hicks C; Madruga JV; Vanveggel S; Stevens M; Boven K;
    HIV Med; 2013 Aug; 14(7):391-400. PubMed ID: 23298380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.
    Leutscher PD; Stecher C; Storgaard M; Larsen CS
    Scand J Infect Dis; 2013 Aug; 45(8):645-51. PubMed ID: 23427878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of the psychiatric side-effects of efavirenz.
    Kenedi CA; Goforth HW
    AIDS Behav; 2011 Nov; 15(8):1803-18. PubMed ID: 21484283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial.
    Dabaghzadeh F; Ghaeli P; Khalili H; Alimadadi A; Jafari S; Akhondzadeh S; Khazaeipour Z
    AIDS Patient Care STDS; 2013 Mar; 27(3):146-54. PubMed ID: 23442031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neurospychiatric symptoms in HIV infected patients and the role of efavirenz].
    Bary M; David F; Gasnault J; Kerneis H; Linard F; Longuet P; Pelissolo A; Ravaux I
    Med Mal Infect; 2004 Oct; 34(10):435-49. PubMed ID: 15747468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications.
    Gaida R; Truter I; Grobler C; Kotze T; Godman B
    Expert Rev Anti Infect Ther; 2016; 14(4):377-88. PubMed ID: 26900637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efavirenz-induced exfoliative dermatitis.
    Zhang JC; Sun YT
    Scand J Infect Dis; 2013 Jan; 45(1):70-2. PubMed ID: 22715849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuropsychiatric effects of efavirenz: delayed onset.
    Dawson S; Woods C
    Int J STD AIDS; 2005 Nov; 16(11):769-70. PubMed ID: 16303077
    [No Abstract]   [Full Text] [Related]  

  • 12. New package inserts for efavirenz and T-20.
    AIDS Clin Care; 2007 Mar; 19(3):24. PubMed ID: 17595717
    [No Abstract]   [Full Text] [Related]  

  • 13. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review.
    Gazzard B; Balkin A; Hill A
    AIDS Rev; 2010; 12(2):67-75. PubMed ID: 20571601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evidence-based therapeutic drug monitoring for efavirenz].
    Solas C; Gagnieu MC;
    Therapie; 2011; 66(3):197-205. PubMed ID: 21819803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
    Crespo M; Ribera E; Suárez-Lozano I; Domingo P; Pedrol E; López-Aldeguer J; Muñoz A; Viladés C; Sánchez T; Viciana P; Teira R; García-Alcalde ML; Vergara A; Lozano F; Galindo MJ; Cosin J; Roca B; Terrón A; Geijo P; Vidal F; Garrido M;
    J Antimicrob Chemother; 2009 Jan; 63(1):189-96. PubMed ID: 18988678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.
    Nelson M; Stellbrink HJ; Podzamczer D; Banhegyi D; Gazzard B; Hill A; van Delft Y; Vingerhoets J; Stark T; Marks S
    AIDS; 2011 Jan; 25(3):335-40. PubMed ID: 21150563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz.
    Dabaghzadeh F; Khalili H; Ghaeli P; Dashti-Khavidaki S
    Expert Opin Pharmacother; 2012 Dec; 13(18):2613-24. PubMed ID: 23140169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of side effects with 2 doses of the HIV drug efavirenz.
    Ann Intern Med; 2009 Aug; 151(3):I24. PubMed ID: 19581632
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.
    Gazzard B; Duvivier C; Zagler C; Castagna A; Hill A; van Delft Y; Marks S
    AIDS; 2011 Nov; 25(18):2249-58. PubMed ID: 21881478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
    Bonnet M; Bhatt N; Baudin E; Silva C; Michon C; Taburet AM; Ciaffi L; Sobry A; Bastos R; Nunes E; Rouzioux C; Jani I; Calmy A;
    Lancet Infect Dis; 2013 Apr; 13(4):303-12. PubMed ID: 23433590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.